SCHEMBL12563259

SCHEMBL12563259

Cc1c(F)cc([C@@H](C)NC(=O)c2coc(Oc3cccc(C(C)C)c3)n2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.40
ROCK2 O75116 6/20 0.39
PDE2A O00408 9/20 0.39
PRKG1 Q13976 3/20 0.39
ROCK1 Q13464 4/20 0.38
PRKACA P17612 2/20 0.38
AKT1 P31749 2/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
CDK1 P06493 1/20 0.38
RPS6KB1 P23443 1/20 0.38
CDK2 P24941 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT2 P31751 1/20 0.38
FLT4 P35916 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
IRAK1 P51617 1/20 0.38
RPS6KA3 P51812 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12563337 0.91 PDE2A (0.41) KLKB1ROCK2PDE2APRKG1ROCK1
SCHEMBL12563373 0.90 KLKB1 (0.42) KLKB1ROCK2PDE2APRKG1KCNQ3
SCHEMBL12563285 0.90 KLKB1 (0.40) KLKB1PDE2AKCNQ3KCNQ2KCNQ4
SCHEMBL12563404 0.90 KLKB1 (0.40) KLKB1ROCK2PDE2APRKG1ROCK1
SCHEMBL12563286 0.90 PTGER4 (0.43) KLKB1ROCK2PDE2AKCNQ3KCNQ2
SCHEMBL12563264 0.89 PDE2A (0.45) KLKB1PDE2A
SCHEMBL12563252 0.88 PTGER4 (0.46) KLKB1PDE2AKCNQ3KCNQ2
SCHEMBL12563250 0.88 PDE2A (0.41) KLKB1PDE2A
SCHEMBL12563326 0.88 PDE2A (0.41) KLKB1PDE2A
SCHEMBL12603590 0.87 KCNQ3 (0.41) KLKB1ROCK2PRKG1ROCK1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME TRPV1, TRPA1, TRPV2 KLKB1 1293/4885ROCK2 4755/4885PDE2A 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.